Last quarter (Q3 2023), Atara Biotherapeutics's total revenue was $2.14M, a decrease of -52.05% from the same quarter last year. In Q3, Atara Biotherapeutics's net income was $-64.57M. See Atara Biotherapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	$ 3.10M	-	-	$ 0.00	$ 0.00	$ 0.00
Cost of Revenue	$ -2.62M	-	-	-	-	-
Gross Profit	$ 5.71M	-	-	-	-	-
Operating Expense	$ 141.99M	$ 344.09M	$ 340.46M	$ 309.05M	$ 295.68M	$ 237.11M
Operating Income	$ -286.99M	$ -280.51M	$ -340.46M	$ -309.05M	$ -295.68M	$ -237.11M
Net Non Operating Interest Income Expense	$ -4.36M	$ -373.00K	$ 29.00K	$ 2.45M	$ 4.72M	$ 6.37M
Other Income Expense	$ -1.96M	$ -1.99M	$ -367.00K	-	-	-
Pretax Income	$ -290.24M	$ -228.29M	$ -340.10M	$ -306.61M	$ -290.96M	$ -230.74M
Tax Provision	$ 6.00K	$ 12.00K	$ 46.00K	$ 15.00K	$ 12.00K	$ -44.00K
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -284.99M	$ -228.28M	$ -340.14M	$ -306.62M	$ -290.98M	$ -230.70M
Basic EPS	$ -3.66	$ -2.24	$ -3.63	$ -4.15	$ -5.67	$ -5.27
Diluted EPS	$ -2.79	$ -2.24	$ -3.63	$ -4.15	$ -5.67	$ -5.27
Basic Average Shares	$ 417.45M	$ 101.99M	$ 93.67M	$ 73.97M	$ 51.31M	$ 43.81M
Diluted Average Shares	$ 417.45M	$ 101.99M	$ 93.67M	$ 73.97M	$ 51.31M	$ 43.81M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 139.38M	$ -344.09M	$ 340.46M	$ 309.05M	$ 295.68M	$ 237.11M
Net Income From Continuing And Discontinued Operation	$ -290.22M	$ -228.30M	$ -340.14M	$ -306.62M	$ -290.98M	$ -230.70M
Normalized Income	$ -126.01M	-	-	$ -306.62M	$ -290.98M	$ -230.70M
Interest Expense	-	-	-	-	-	-
EBIT	$ -285.88M	$ -228.29M	$ -340.12M	$ -309.05M	$ -295.68M	$ -237.11M
EBITDA	$ -283.56M	$ -222.59M	$ -330.82M	$ -300.72M	$ -288.61M	$ -233.38M

Currency in USD

Atara Biotherapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing